LTGO
Latigo Biotherapeutics, Inc. Common Stock (LTGO)
Healthcare • NASDAQ • $22.37+4.53%
- Symbol
- LTGO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $22.37
- Daily Change
- +4.53%
- Market Cap
- $1.17B
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $22.47
- 52W Low
- $17.22
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- N/A
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Company websiteResearch LTGO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.